Title: Male Breast Carcinoma – A Comprehensive Analysis between Tumor Characteristics, Hormone Receptor Status and its Impact on Survival
Authors: Dr Arpit Jain, Dr Anuj Gupta, Dr Seema Mutha, Dr Shuchita Pathak, Dr Ajay Baphna
DOI: https://dx.doi.org/10.18535/jmscr/v8i10.32
Abstract
Introduction: Male breast cancer is a rare cancer. Male breast cancer is most common in older men, though it can occur at any age. Male breast cancer is staged (reflecting the extent of tumor spread) identically to breast cancer in women. Surgery is the most common initial treatment for male breast cancer. Depending on the situation, chemotherapy, radiation therapy, and hormonal therapy are also considered as part of the care plan
Aim: To analyse relationship between clinical profile of tumor with hormonal receptor status and their impact on survival in male breast carcinoma patients of North India.
Methodology: It is a retrospective analysis of total 32 patients from 2010 to 2016 presented at Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur.
Results: Median age of presentation was 62 years and Her-2 positive patients belonged to younger age group (< 50 years). Mean duration of symptoms was 3.5 months but Her 2 positive tumors presented relatively earlier with advanced diseases. Most common stage was stage II. Maximum patients belonged to T2N0 group but higher T staging and nodal burden was noted in Her 2 positive and TNBC group. Four patients developed distant metastasis and among those 3 patients died in their 5 year follow up, all were from TNBC and Her 2 positive group. The median follow up was 60 months. The impact of hormone status and Her 2 expression was found statistically significant with T stage and Nodal status. The DFS was found significantly better in HR+/Her2 - patients in comparison to Her 2 positive or TNBC group. Her2 expression & TNBC confers lower 5 year actuarial overall survival but did not reached statistically significant value.
Conclusion: Male breast carcinoma is relatively rare entity and management principals are same as female breast carcinoma. Early presentation and favorable hormonal profile supports for a better disease free survival and 5 year overall survival but because of aggressive disease behavior with Her 2 positivity and TNBC, still holds poor outcome.
Keywords: Male breast Cancer, Hormone Receptor, Tumor Characteristic.
References
- F. Cardoso, J. M. S. Bartlett, L. Slaets, C. H. M. van Deurzen, E. van Leeuwen-Stok, P. Porter et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of Oncology 2018;29: 405–417.
- Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010; 28(2): 232–239.
- J. Ruddy ,E. P. Winer. Male breast cancer: risk factors, biology, diagnosis,treatment, and survivorship. Annals of Oncology 2013; 24: 1434–1443.
- Shukla NK, Seenu V, Goel AK, Raina V, Rath GK, Singh R, et al. Male breast cancer: A retrospective study from a regional cancer center in Northern India. J Surg Oncol 1996;61:143‑
- Mitra D, Manna A, Sikdar SK, Sur PK. Clinicopathological study and its prognostic implication in male breast carcinoma. J Indian Med Assoc 2007;105:681‑3, 686.
- Ram D, Rajappa SK, Selvakumar VP, Shukla H, Goel A, Kumar R, et al. Male breast cancer: A retrospective review of clinical profile from a tertiary cancer care center of India. South Asian J Cancer 2017;6:141-3.
- Blin N, Kardas I, Welter C et al. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology 1993; 50(6): 408–411.
- Joshi MG, Lee AK, Loda M et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996; 77(3): 490–498.